Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review

Caruso, Rosario Alberto; Parisi, Antonio; Bonanno, Anna; Paparo, Domenica; Quattrocchi, Emilia; Branca, Giovanni; Scardigno, Marco; Fedele, Francesco

doi:10.3892/ol.2011.420

Cited by 44 publications

(33 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mechanisms similar to coagulative necrosis might speculatively act at the centers of rapidly growing solid tumors to promote tumor growth by neovasularization, 15,16 although this is speculative.…”

Section: Morphological Aspects Of Necrosismentioning

confidence: 99%

The in vivo evidence for regulated necrosis

Tonnus

Linkermann

2017

Immunological Reviews

103

View full text Add to dashboard Cite

Necrosis is a hallmark of several widespread diseases or their direct complications. In the past decade, we learned that necrosis can be a regulated process that is potentially druggable. RIPK3- and MLKL-mediated necroptosis represents by far the best studied pathway of regulated necrosis. During necroptosis, the release of damage-associated molecular patterns (DAMPs) drives a phenomenon referred to as necroinflammation, a common consequence of necrosis. However, most studies of regulated necrosis investigated cell lines in vitro in a cell autonomous manner, which represents a non-physiological situation. Conclusions based on such work might not necessarily be transferrable to disease states in which synchronized, non-cell autonomous effects occur. Here, we summarize the current knowledge of the pathophysiological relevance of necroptosis in vivo, and in light of this understanding, we reassess the morphological classification of necrosis that is generally used by pathologists. Along these lines, we discuss the paucity of data implicating necroptosis in human disease. Finally, the in vivo relevance of non-necroptotic forms of necrosis, such as ferroptosis, is addressed.

show abstract

Section: Morphological Aspects Of Necrosismentioning

confidence: 99%

The in vivo evidence for regulated necrosis

Tonnus

Linkermann

2017

Immunological Reviews

103

View full text Add to dashboard Cite

show abstract

“…In 34 cases, specimen was procured using CT guidance, in 12 cases via bronchoscopy, and in 1 case using ultrasound guidance. In 21 cases (CT guided [16] cases and endobronchial [5] cases), paired FNA and NCB specimens were obtained, in 18 cases (CT guided [16], endobronchial [1], and USG [1]) only NCB were obtained and in 8 cases (CT guided [2], endobronchial [6]) only FNA was available. Knowledge of clinical history and/or previous cytological or histological material was available for review in 39 cases, due to which either none or at most 2 immunostains were performed to attain a definitive diagnosis in 30 cases (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…In our study, all 8 cases had elongated columnar cells but necrosis was seen (focal or extensive) in only 2 cases. Besides, necrosis can be seen in primary carcinomas of the lung as well, most commonly squamous cell and large cell undifferentiated carcinoma thereby undermining its utility . Also of note is that the features described above only suggest colorectal differentiation but not a colorectal primary, as WHO has recently recognized pulmonary adenocarcinoma with enteric differentiation (PAED) as a rare subtype of lung adenocarcinoma classification.…”

Section: Discussionmentioning

confidence: 99%

“…Besides, necrosis can be seen in primary carcinomas of the lung as well, most commonly squamous cell and large cell undifferentiated carcinoma thereby undermining its utility. 5 Also of note is that the features described above only suggest colorectal differentiation but not a colorectal primary, as WHO has recently recognized pulmonary adenocarcinoma with enteric differentiation (PAED) as a rare subtype of lung adenocarcinoma classification. The observed decrease or loss of immunoreactivity for TTF-1 and Napsin A in this subtype can lead to a misdiagnosis of metastatic colorectal carcinoma.…”

Section: Metastatic Colorectal Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

Role of cytology and immunochemistry in diagnosis of metastatic malignancies in the lung: A critical appraisal

Manucha

Hansen

González

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

Background Lung is one of the most common sites for primary and metastatic malignancies and a challenging site to diagnose primary versus a metastatic origin of the tumor on cytology. Pathologic diagnosis of the site of origin of cancer has major implications in the management and staging purposes and may have to be followed by testing for predictive/prognostic markers. The clinical history of a known extrapulmonary primary and the radiologic findings of multiple nodules in the lung are useful in arriving at the right diagnosis but is not always available. Rarely pulmonary metastasis may be the first manifestation of an extrapulmonary tumor or may even present as a single nodule. Method In this study, we reviewed cytomorphologic features of tumors metastatic to the lung (2014‐2017) in conjunction with immunochemistry and evaluation of needle core biopsy when available. The review of the slides was performed with an emphasis on our ability to identify the site of origin in the tumors. Results We identified 47 cases of metastatic tumors in the lung diagnosed on cytology. Clinical history was available in 83% cases and with aid of immunostains, a definitive diagnosis on the origin of the tumor was made in all these cases. In the remaining 8 cases, a primary origin could only be suggested. The use of immunochemistry facilitated the diagnosis but could be misleading. Conclusion The approach to the diagnosis of metastatic tumors in the lung on cytology should be largely guided by the previous clinical history and comparison with previous tissue/cellular material if available.

show abstract

“…Two separate studies have shown that ctDNA was more likely to be detected among patients with squamous cell carcinoma than adenocarcinoma (27,28). This is thought to be due to a higher rate of tumor necrosis and passive DNA release among patients with squamous cell carcinoma.…”

Section: Next Generation Sequencingmentioning

confidence: 98%

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer

Marmarelis¹,

Thompson²,

Aggarwal³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Targeted therapies have dramatically changed the treatment paradigm for a select group of patients with non-small cell lung cancer (NSCLC) whose tumors harbor targetable genetic aberrations.Patients with such genetic changes enjoy excellent responses to tyrosine kinase inhibitors (TKIs), but resistance is nearly inevitable. Resistance to first line TKIs is heterogeneous and multifactorial-multiple resistance mechanisms have been reported, and different metastatic foci in the same patient may have distinct resistance mechanisms. The recent approval of next-generation TKIs specific to particular resistance mechanisms, and the likely future approval of others, necessitates the acquisition of repeat molecular analysis at time of progression. Tumor tissue has traditionally been the preferred source to detect oncogenic driver and resistance mutations, but tissue biopsies are invasive and often difficult to obtain. The use of circulating tumor DNA (ctDNA), so-called "liquid biopsies", has emerged as a promising technique to molecularly profile tumors non-invasively and is becoming increasingly utilized in the routine management of lung cancer. This review will describe the current role of ctDNA in the management of lung cancer, and explore emerging data that point towards its increasingly important role in clinical care.

show abstract

Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review

Cited by 44 publications

References 20 publications

The in vivo evidence for regulated necrosis

The in vivo evidence for regulated necrosis

Role of cytology and immunochemistry in diagnosis of metastatic malignancies in the lung: A critical appraisal

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer

Contact Info

Product

Resources

About